Pharmacokinetics of human chorionic gonadotropin injection in obese and normal-weight women

What Was Tested

Researchers studied hCG (human chorionic gonadotropin) in this randomized controlled trial publication.

Obese women have poorer in vitro fertilization outcomes, but underlying mechanisms remain unclear.

Who Took Part

By PubMed's age tags, the people studied were teenagers, young adults and adults, women only.

This was a randomized, experimental study.

Twenty-two women aged 18-42 years with body mass index of 18.5-24.9 (normal) or 30-40 kg/m(2) (obese).

How the Study Was Run

The researchers set it up as a randomized and pilot study.

The participants were allocated by chance, so the hCG (human chorionic gonadotropin) group and the comparison group should start out alike.

It is described as a pilot, a small early test of whether a larger hCG (human chorionic gonadotropin) study would be practical.

A time span of 4 weeks appears in the methods.

Participants received im urinary hCG or s.c. recombinant hCG and returned for a second injection type after a 4-week washout.

Intramuscular injections were performed under ultrasound guidance.

Blood was taken 0, 0.5, 1, 2, 4, 6, 8, 12, 24, and 36 hours after injection.

What Was Measured

Obese women have poorer in vitro fertilization outcomes, but underlying mechanisms remain unclear.

The subject headings attached to it are Chorionic Gonadotropin, Ideal Body Weight, Obesity, Pilot Projects and Skinfold Thickness.

What This Means in Plain Language

The paper is a randomized and pilot study of hCG (human chorionic gonadotropin) over 4 weeks.

Results are reported in around 8 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2014 (The Journal of clinical endocrinology and metabolism), a journal based in United States.

More context: the hCG (human chorionic gonadotropin) compound page, all human trials.